Loading
A phase 3 trial of Dacomitinib and Erlotinib in Non-small-cell lung cancer, run by Pfizer, completed.
ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT01360554 by Pfizer, with 878 participants recorded, started 2011-06-16 and reaching its primary completion in 2013-09-30. Interventions recorded: Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804. Conditions recorded: Non-Small Cell Lung Cancer.
Linked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
878 enrolled.
95% CI 1.9 to 2.8; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication · 95% CI 1.9 to 2.8
Source95% CI 1.9 to 2.9; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication · 95% CI 1.9 to 3.0
Source95% CI 6.8 to 9.0; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication · 95% CI 7.4 to 9.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Per Independent Radiologic Review.primary | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 439 | 2.6 months | 0.933 (0.797 to 1.093) | 0.195 | link |
| Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 439 | 2.5 months | ||||
| Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.primary | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 256 | 2.6 months | 1.037 (0.848 to 1.268) | 0.643 | link |
| Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 263 | 2.5 months | ||||
| Overall Survival (OS). | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 439 | 7.9 months | 1.026 (0.887 to 1.188) | 0.638 | link |
| Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 439 | 8.3 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dacomitinib, Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/